HCWB insider filings
HCW Biologics Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-07-31. Screen HCWB transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 3 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 3 filings by 3 insiders — 38,682 shares, $99,993 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 23,210 shares @ $2.58 ($59,998) by Wong Hing C, filed 2026-07-31.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Wong Hing C — Chief Executive Officer, Director, 10% owner | 1 | 1 leg · 23,210 sh · $59,998 | — | — |
| Flowers Lee — SVP of Business Development | 1 | 1 leg · 7,736 sh · $19,998 | — | — |
| GARRETT SCOTT T — Director | 1 | 1 leg · 7,736 sh · $19,998 | — | — |
Recent insider filings — HCW Biologics Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-31 | 4 | Wong Hing C — Chief Executive Officer, Director, 10% owner | Purchase (P): 23,210 @ $2.58 | EDGAR |
| 2026-07-31 | 4 | Flowers Lee — SVP of Business Development | Purchase (P): 7,736 @ $2.58 | EDGAR |
| 2026-07-31 | 4 | GARRETT SCOTT T — Director | Purchase (P): 7,736 @ $2.58 | EDGAR |
| 2026-05-27 | 4 | Wong Hing C — Chief Executive Officer, Director, 10% owner | Purchase (P): 113,879 @ $1.41 · Purchase (P): 113,879 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Byam Rebecca — Chief Financial Officer | Purchase (P): 14,235 @ $1.41 · Purchase (P): 14,235 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | GARRETT SCOTT T — Director | Purchase (P): 177,936 @ $1.41 · Purchase (P): 177,936 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Wong Hing C — Chief Executive Officer, Director, 10% owner | Purchase (P): 8,054 @ $7.45 | EDGAR |
| 2025-05-20 | 4 | Winer Gary M — Director | Purchase (P): 1,342 @ $7.45 | EDGAR |
| 2025-05-20 | 4 | GARRETT SCOTT T — Director | Purchase (P): 13,423 @ $7.45 | EDGAR |
| 2025-05-09 | 4 | Wong Hing C — Chief Executive Officer, Director, 10% owner | Purchase (P): 92,500 @ $26 · Purchase (P): 46,250 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | Byam Rebecca — Chief Financial Officer | Purchase (P): 8,462 @ $26 · Purchase (P): 4,231 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | Flowers Lee — SVP of Business Development | Purchase (P): 962 @ $26 · Purchase (P): 481 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | Greene Rick S. — Director | Purchase (P): 962 @ $26 · Purchase (P): 481 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | Winer Gary M — Director | Purchase (P): 2,308 @ $26 · Purchase (P): 1,154 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | GARRETT SCOTT T — Director | Purchase (P): 5,385 @ $26 · Purchase (P): 2,692 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Greene Rick S. — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Winer Gary M — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Giles Lisa M. — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | GARRETT SCOTT T — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-02-22 | 4 | Wong Hing C — Chief Executive Officer, Director | Grant/award (A): 739,288 @ $1.40 | EDGAR |
| 2024-02-22 | 4 | Greene Rick S. — Director | Grant/award (A): 35,714 @ $1.40 | EDGAR |
| 2024-02-22 | 4 | Flowers Lee — SVP of Business Development | Grant/award (A): 71,429 @ $1.40 | EDGAR |
| 2024-02-22 | 4 | Byam Rebecca — Chief Financial Officer | Grant/award (A): 760,714 @ $1.40 | EDGAR |
| 2024-02-22 | 4 | Giles Lisa M. — Director | Grant/award (A): 35,715 @ $1.40 | EDGAR |
| 2024-02-22 | 4 | GARRETT SCOTT T — Director | Grant/award (A): 142,858 @ $1.40 | EDGAR |
| 2023-12-11 | 4 | Rhode Peter — See Remarks | Option exercise (M): 14,000 @ $0.14 · Option exercise (M): 14,000 (derivative) @ $0 | EDGAR |
| 2023-12-11 | 4 | Flowers Lee — SVP of Business Development | Option exercise (M): 7,501 @ $0.14 · Option exercise (M): 7,501 (derivative) @ $0 | EDGAR |
| 2023-11-20 | 4 | Rhode Peter — See Remarks | Option exercise (M): 15,000 @ $0.14 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2023-10-23 | 4 | Byam Rebecca — Chief Financial Officer | Option exercise (M): 47,249 @ $0.14 · Option exercise (M): 47,249 (derivative) @ $0 | EDGAR |
| 2023-09-18 | 4 | Wong Hing C — Chief Executive Officer, Director | Purchase (P): 1,800 @ $2.08 | EDGAR |
| 2023-09-15 | 4 | Byam Rebecca — Chief Financial Officer | Purchase (P): 5,000 @ $2.10 | EDGAR |
| 2023-09-15 | 4 | Winer Gary M — Director | Purchase (P): 500 @ $2.05 · Purchase (P): 46 @ $2 · Purchase (P): 162 @ $2.08 · Purchase (P): 879 @ $2.05 | EDGAR |
| 2023-09-13 | 4 | Byam Rebecca — Chief Financial Officer | Purchase (P): 5,000 @ $2.05 · Purchase (P): 5,000 @ $2.09 | EDGAR |
| 2023-09-12 | 4 | Winer Gary M — Director | Purchase (P): 1 @ $1.90 · Purchase (P): 99 @ $2.05 · Purchase (P): 500 @ $2.05 | EDGAR |
| 2023-09-08 | 4 | Byam Rebecca — Chief Financial Officer | Purchase (P): 5,000 @ $1.95 · Purchase (P): 5,000 @ $2.02 | EDGAR |
| 2023-09-07 | 4 | Byam Rebecca — Chief Financial Officer | Purchase (P): 5,000 @ $1.95 | EDGAR |
| 2023-09-07 | 4 | Winer Gary M — Director | Purchase (P): 400 @ $1.75 · Purchase (P): 63 @ $1.95 | EDGAR |
| 2023-06-15 | 4 | Greene Rick S. — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Winer Gary M — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Giles Lisa M. — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | GARRETT SCOTT T — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Flowers Lee — SVP of Business Development | Option exercise (M): 5,356 @ $0.14 · Purchase (P): 10,000 @ $2.16 · Option exercise (M): 5,356 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Byam Rebecca — Chief Financial Officer | Purchase (P): 20,000 @ $2.06 | EDGAR |
| 2023-06-08 | 4 | Byam Rebecca — Chief Financial Officer | Purchase (P): 20,000 @ $2.03 · Purchase (P): 4,696 @ $2.21 | EDGAR |
| 2023-06-07 | 4 | Byam Rebecca — Chief Financial Officer | Purchase (P): 20,000 @ $1.67 · Purchase (P): 19,062 @ $1.82 | EDGAR |
| 2023-06-02 | 4 | Wong Hing C — Chief Executive Officer, Director | Purchase (P): 800 @ $1.62 · Purchase (P): 800 @ $1.54 | EDGAR |
| 2023-06-01 | 4 | Wong Hing C — Chief Executive Officer, Director | Purchase (P): 3,000 @ $1.55 · Purchase (P): 2,000 @ $1.55 | EDGAR |
| 2023-06-01 | 4 | Winer Gary M — Director | Purchase (P): 850 @ $1.52 · Purchase (P): 500 @ $1.50 | EDGAR |
| 2023-05-31 | 4 | Byam Rebecca — Chief Financial Officer | Purchase (P): 20,000 @ $1.62 · Purchase (P): 20,000 @ $1.66 | EDGAR |
| 2023-05-24 | 4 | Byam Rebecca — Chief Financial Officer | Purchase (P): 33,450 @ $1.53 · Purchase (P): 5,036 @ $1.57 · Purchase (P): 20,000 @ $1.61 | EDGAR |
Recent 8-K events — HCW Biologics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-10 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-14 | 8-K | 4.02 — Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | EDGAR |
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-01 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-30 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — HCW Biologics Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-299271 (S-1) — latest: Initial registration (S-1), filed 2026-10-02
- SEC file 333-298452 (S-1) — latest: Amendment (S-1/A), filed 2026-08-28
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=HCWB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →